Welcome to the HBV
Advocate’s AASLD Conference coverage. In
an effort to best serve our readership, we will post all the important and
interesting abstracts about HBV from the conference. While attending the conference, we will update
any abstracts that we personally cover
at the conference. The updated abstracts will be marked with the date that they
have been updated and posted. The other
abstracts posted to the web site are HBV related abstracts posted to www.aasld.org that we have not been able to
report on or update.
To locate specific
abstracts for each topic below, click on the links.
Please click here
to view our fact sheet on reading and understanding an abstract.
Thank You,
Alan Franciscus
Editor-in-Chief
Hepatitis B
Antivirals
·
Adefovir
o
946.Characterization of
Hepatitis B Virus Polymerase Mutations Detected During Antiviral Treatment with
Adefovir Dipivoxil (ADV)
o
955. Drug Susceptibility
Testing of a Novel Mutation Pattern (A181S+M204I) Conferring Resistance to
Lamivudine and Adefovir Dipivoxil
o
956.Adefovir Dipivoxil Plus
Lamivudine Combination Treatment Is Superior to Adefovir Dipivoxil Monotherapy
in Lamivudine-resistant Hepatitis B e Antigen-negative Chronic Hepatitis B
Patients
o
961. The Effect of Lamivudine
and Adefovir Dipivoxil on Preventing Hepatocellular Carcinoma in Hepatitis B
Virus-related Liver Cirrhosis
o
964. Mutations of the
HBV-polymerase Gene Associated with Adefovir Drug Resistance in Patients
Undergoing a First Adefovir Therapy
o
981. Clinical Covariates
Associated with Virological Response and Adefovir Resistance in Chronic
Hepatitis B (HbeAg)- negative Lamivudine-resistant Patients Treated with
Adefovir Alone or in Combination with Lamivudine for 28 months
o
982. Factors Affecting
Response To Adefovir Treatment In Patients With Chronic Hepatitis B And
Lamivudine Resistance
o
983. Predictors of Virologic
Response and Resistance to Adefovir in Patients With Lamivudine-resistant
Chronic Hepatitis B Virus Infection
o
996. Impact of Adefovir
Dipivoxil on Liver Fibrosis and Activity Assessed with FibroTest-ActiTest in Patients
Infected by Hepatitis B Virus
o
998. Factors Affecting Initial
Virologic Response and Emergence of Resistant Mutants after Adefovir Treatment
in Lamivudine-resistant Chronic Hepatitis B Patients
o
1000. Adefovir Depivoxil for
Decompensated Liver Cirrhosis Patients with Lamivudine-resistant Hepatitis B:
Multi-center Long-term Results
·
Entecavir
o
938. Four-Year Entecavir Treatment in
Nucleoside-Naďve HBeAg(+) Patients: Results from Studies ETV-022 and -901
o
951. Entecavir: A Rescue Therapy for Chronic
Hepatitis B Patients with a Limited Virological Response to Adefovir?
o
963. Emergence of Hepatitis B Virus Gene
Mutation Related to Entecavir-resistance in Chronic Hepatitis B Patients
Participating in the Phase 2 Clinical Studies of Entecavir in Japan
o
997. Long-term Follow-up of Entecavir
Treated Protocol-defined Nonresponders in Rollover Study ETV-901
o
1003. Three-year Assessment of Entecavir
Resistance in Genotype C Chronic Hepatitis B Patients in Japan Reveals
Different Clinical Outcomes Regarding Breakthrough Hepatitis Predicted by the
Resistance Substitutions Using Recently-developed INNO-LiPA HBV Assay
·
Lamivudine
o
957. Pretreatment Alanine
Transaminase Level Might Not Be the Most Important Factor in Predicting HBeAg
Loss in Older Patients with More Prolonged HBV Infection
o
947. Durability of Antiviral
Response in Lamivuidne-Treated HBeAg Positive Chronic Hepatitis B Patients Who
Did Not Relapse Within a Year of Post-Treatment
o
948. Analysis of Determinants
for Sustained Virologic Response to Lamivudine Monotherapy in Patients with
HBeAg Positive Chronic Hepatitis B: A Multi-center Trial
o
950. Variability of the HBV
Pol Gene Reverse-Transcriptase Domain in Viral Isolates from Untreated and
Lamivudine-resistant Chronic Hepatitis B Patients
o
956. Adefovir dipivoxil plus
lamivudine combination treatment is superior to adefovir dipivoxil monotherapy
in lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B
patients
o
957. Pretreatment Alanine
Transaminase Level Might Not Be the Most Important Factor in Predicting HBeAg
Loss in Older Patients with More Prolonged HBV Infection
o
959. Does the Genotoxic Effect
of Lamivudine Treatment in Chronic Hepatitis B to the Host DNA?
o
966. Prediction of Long-term
Maintenance of Virologic Response During Lamivudine Treatment in HBeAg-Negative
Chronic Hepatitis B
o
972. Long-term Follow-up of
Chinese Patients with HBeAg-negative Chronic Hepatitis B Who Discontinued
Treatment after Twp Years of Lamivudine Monotherapy
o
977. Restoration of
HBV-Specific T Cell Responses in Lamivudine Long-term Responder
o
989. Profiles of HBV DNA, ALT and
HBeAg Status After Stopping Lamivudine in Patients with HBeAg Seroconversion
o
999. Prognostic Factors that
Associated with Hepatitis B Virus DNA Breakthrough in Chronic Hepatitis B
Patients with Lamivudine Treatment
·
Telbivudine
o
940. Creatine Kinase (CK) Elevations and
Muscle Toxicities Associated with Chronic Telbivudine (LdT) Use in Prospective
Clinical Trials
o
994. Baseline Parameters Predict Both
Early Virologic Response and Longer Term Outcomes for Telbivudine-Treated
Patients With Chronic Hepatitis B (The Globe Study)
o
995. On-Treatment Virologic Suppression at
Week 24 Decreases the Risk of Histologic Progression at One Year; Data from the
GLOBE Trial
·
Tenofovir
o
LB6. A Randomized, Double-Blind,
Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the
Treatment of HBeAg Positive Chronic Hepatitis B (CHB): Study GS-US-174-0103
o
83. First Multicenter Evaluation of the
Efficacy of Tenofovir in Nucleos(t)ide Analog Experienced Patients with HBV
Monoinfection
o
LB2. A Randomized, Double-Blind,
Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the
Treatment of HBeAg-Negative Chronic Hepatitis B (CHB): Study GS-US-174-0102
o
960. Tenofovir Shows Limited Efficacy in
Treatment of HBV Infections Resistant Against Adefovir
Antiviral
Resistance/Mutations
·
949. Multidrug Resistance and
Cross-Resistance Pathways in HBV as a Consequence of Treatment Failure
·
976. Drug Resistance Mutation
Analysis by Different Methods in a Highly Treatment-experienced Chronic
Hepatitis B Patient Population
·
980. Very High Prevalence of
Precore (preC) and/or Basal Core Promoter (BCP) Mutations (Mut) in
HBeAg-positive (eAg+) and -negative (eAg-) Chronic Hepatitis B (CHB) Especially
Among Older Patients
·
986. A Hepatitis B Virus
Mutant Implicated In Non-Response To Sequential Treatment With Adefovir,
Lamivudine And Entecavir Shows Cross-Resistance To Multiple Antiviral Agents
·
987. Cost-effectiveness of
New Treatment Paradigms for HBeAg-negative Chronic Hepatitis B
·
1005. Cross-resistance
Characterization of the Main HBV Drug-resistant Mutants
·
1006. Detection of Hepatitis
B Virus YMDD Mutants by Mltiplex-PCR Using Dual Priming Oligonucleotide (DPO)
·
1007. Five-year
Retrospective Survey of HBV Genotypic Drug Resistance Patterns in a Database of
381 HBV Reverse Transcriptase Sequences in Southern France.
Children and
HBV
·
1090. Unique Full Length
Hepatitis B Virus Genomes Isolated from Children With Hepatocellular Carcinoma
·
1093.Treatment of Hepatitis B
Using Intron A vs. Peginterferon in Combination with Lamivudine in Children
·
1094. HBeAg Seroconversion Correlates
with a High Number of Core Gene Mutations and with Genotypes B and D in
Pediatric Patients
·
1095. Graft Histology Up to 10
Years after Pediatric Liver Transplantation: High Incidence of Severe Fibrosis,
Correlated with Transplant-related Factors
·
1095. Graft Histology Up to 10
Years after Pediatric Liver Transplantation: High Incidence of Severe Fibrosis,
Correlated with Transplant-related Factors
Disease
Progression
·
897. In Vitro Infection of
Immortalized Human Hepatocytes by Hepatitis B Virus and Its Application to
Anti-viral Treatment
·
898. The Role of Serial
Measurement of Serum HBV-DNA Levels in Patients with Chronic HBeAg(-) Hepatitis
B Infection; Association with Liver Disease Progression: A Prospective Cohort
Study
·
900. Large Scale Longitudinal
Study of Chronic Hepatitis B Patients with Hepatitis B Surface Antigen
Seroclearance
·
902. Reduced HBV Rreplication
in HBeAg-negative Patients Is Due to Lower Covalently Closed Circular DNA
Content and Impaired Virion Productivity
·
903. High Viral Load and
Hepatitis B Virus (HBV) Subgenotype Ce Have Increased Risk of Hepatocellular
Carcinoma (HCC) – A 7-year Prospective Follow-up Study
HIV/HBV
Coinfection
·
1480. Liver Disease
Progression Among HIV-infected Patients with Viral Hepatitis
Interferon
·
941. Mutations in Immunodominant Epitopes
of Hepatitis B Virus (HBV) Core Region: Enhancement of Viral Evolution by the
Effect of Interferon Therapy
·
953. Demonstration of an Association
Between Detection of IgG Antibody Reactivity Towards the C-terminal Region of
the preS1 Protein of Hepatitis B Virus and the Capacity to Respond to
Interferon Therapy in Chronic Hepatitis B
·
109. In vitro and in vivo Inhibition of
HBV Replication by Peptide Aptamers via Disruption of the HBX-Proteasome
Interaction
·
962. The Indication and Limitation of
Interferon Therapy as the First Line Therapy of Chronic Hepatitis B from the
Histological Analysis of 800 Chronic Hepatitis B Patients
·
1002. Predicting Sustained HBeAg Loss after
Treatment with Peginterferon alpha-2b: Development and Validation of a
Practical Model
·
965. Sustained HBeAg and HBsAg Loss after
Long-term Follow-up of HBeAg-Positive Patients Treated with Peginterferon
alpha-2b
·
974. Not HBeAg-status But HBV Genotype
Predicts Response to Interferon in Chronic hepatitis B
·
978. Twenty-four Weeks of Therapy with
Peginterferon alfa-2a Is Similar to 48 weeks of Therapy in Patients with
HBeAg-positive Chronic Hepatitis B and Good Predictors of Response
·
979. Long-term Follow-up of HBsAg
Clearance in Patients with HBeAg-negative CHB Treated with Peginterferon
alfa-2a: Increase in HBsAg Clearance Rate from 3% Six Months Post-treatment to
8% after Three Years
·
990. Reduction in Serum HBsAg Level in
Patients with Chronic Hepatitis B Infected with Genotype D Induced by
(pegylated) Interferon alfa-2a Alone or in Combination with Nucleos(t)ide
Analogs: A Long-term Single Center Cohort Study
·
991. High Rates of HBsAg Seroconversion in
Chronic Hepatitis B Patients Responding to Interferon Therapy: a Long-term
Follow-up Study
·
992. HBsAg Seroconversion: Different
Kinetics of Serum HBsAg Level Decrease in Inactive Carriers and Chronic Hepatitis
B Patients Treated with Interferon
Liver Cancer
·
374. The Effect of Sustained HBV
Viremia on the Recurrence of Hepatocellular Carcinoma After Curative Resection
·
376. Early Diagnosis Panel of Serum
Biomarkers of HBV-Induced Hepatocellular Carcinoma During 3 Years Follow-up
·
389. MicroRNA Expression Profiling
Combined with Analysis of Target Gene Expression in Chronic Viral Hepatitis and
Hepatocellular Carcinoma
·
397. Polymorphisms of DNA Repair
Genes XRCC3, ERCC5/XPG and Risk of Hepatocellular Carcinoma in Korean with
Chronic Hepatitis B Infection
·
400. Hepatitis B Virus X Gene
Mutations Are Common in Patients Both With or Without Hepatocellular Carcinoma
and Further Mutations Occur When Hepatocellular Carcinoma Develops
·
401. Trends in the Incidence of
Hepatocellular Carcinoma in Singapore 1968-2002
·
402. The Changing Epidemiology and
Etiology of Hepatocellular Carcinoma from 1969 Through 2006 in Alaska Native
People
·
403. Prognostic Factors Affecting 3
Years Survival in Patients with Hepatocellular Carcinoma (HCC
·
411. Polymorphism of Interleukin-18
Is a Risk Factor for the Clearance of Hepatitis B Virus Infection and
Hepatocellular Carcinoma Development
·
415. Genetic Polymorphisms Associated
with Clearance of Hepatitis B Virus Infection and Hepatocellular Carcinoma
Occurrence Detected by SNP Chips
·
420. Serum Antibody to Hepatitis B
Core Antigen Is Not Associated with Increased Risk of Hepatocellular Carcinoma
(HCC) in Patients with HCV-related Cirrhosis
Liver
Transplantation
·
11. A Randomized Study to Assess the Safety
and Efficacy of Adefovir Dipivoxil Substitution for Hepatitis B Immune Globulin
in Liver Transplantation Patients Receiving Long-term Low-dose IM HBIg and
Lamivudine Prophylaxis
·
12. Decline in the Need for Liver
Transplantation for End Stage Liver Disease secondary to Hepatitis B in the
United States
·
28. Survival and Risk of Hepatitis B
Virus (HBV) Recurrence in HIV-HBV Coinfected Liver Transplant Recipients:
Preliminary Findings from the HIV-TR Study
New
Antivirals
·
952. Combination Antiviral Effects
of 2’, 3’-dideoxy-3’fluoroguanosine with Nucleos(t)ide Analogs Against
Hepatitis B Virus In-vitro
·
110. Induction of Antigen-specific Humoral and
Cellular Immune Responses by Antigen-pulsed Human Blood Dendritic Cells in
Hepatitis B Vaccine Nonresponders and Patients with Chronic Hepatitis B
·
111. Powerful inhibition of
hepatitis B virus replication by CpG-induced cytokines in combination with
lamivudine in vitro
·
1121. Long-Term Inhibition of
Hepatitis B Virus Replication Using the Non-viral Episomal Vector pEPI-1
·
113. Adeno-associated Virus Rep78
Protein Inhibits Human Hepatitis B Virus Replication in Human Cells by Binding
to X Promoter and C Promoter of HBV
·
114. Construction of the shRNA
Plasmid of Human fgl2 Prothrombinase Gene and Its Effect on hfgl2 Expression
In-vitro
·
985. Hepatitis B Surface Antigen
Titer Was Decreased During Clevudine Therapy
·
1004. The Effects of
α-galactosylceramide on Chronic Hepatitis B Infection in a Randomized
Placebo-Controlled Phase I/II Trial
Prevention
and Screening
·
1457. Screening for
Hepatitis B Virus (HBV) Infection by Primary Care Physicians in New York City: Are
Screening Recommendations for Persons Born in Endemic Countries Being Followed?
·
1473. Clinical and
Laboratory Characteristics of Pregnant Women Chronically Infected with
Hepatitis B Virus (HBV)
·
147. A Novel
Therapeutic HBV Vaccine Induces Potent Surface- and Core-specific
Immunogenicity in Mice, Rhesus Macaques and HBV Transgenic Mice
·
967. Amino Acid
Variability within Hepatitis B Surface Antigen and the Overlapping Reverse
Transcriptase Region in HBsAg-Negative/HbcAb-Positive Patients Presenting HBV
Reactivation While Undergoing Chemotherapy and/or Stem Cell Transplantation for
Cancer
·
970. Liver Biopsy:
Still Essential in the Management of Chronic Hepatitis B
·
975. Intrahepatic and
Serum Markers of HBV Replication and Their Relationship to Serum HBeAg Titers:
Implications for the Use of Quantitative HBeAg Testing as a Predictive Tool for
Treatment Outcome
·
984. Management of
Chronic Hepatitis B Virus (HBV) Infection by Primary Care Physicians in Urban
Hospitals and Clinics in New York City
·
988. Screening for
Hepatitis B in Chemotherapy Patients: Survey of Current Oncology Practices
·
993. High Prevalence of
Significant Histologic Disease in Patients with Chronic Hepatitis B and Normal
ALT
·
1001. Clinical
Features of Lymphoma Chemotherapy Associated Hepatitis Virus B Reactivation.
·
1008. Inflammation and
Fibrosis in Patients with Chronic Hepatitis B Despite Low Viral Load at the
Time of Liver Biopsy
·
901. FibroTest® (FT)
and ActiTest® (AT) Accurately Predict Risk of Liver Decompensation and Death in
Patients with Chronic Hepatitis B (CHB)
·
1457. Screening for
Hepatitis B Virus (HBV) Infection by Primary Care Physicians in New York City:
Are Screening Recommendations for Persons Born in Endemic Countries Being
Followed?
·
1473. Clinical and
Laboratory Characteristics of Pregnant Women Chronically Infected with
Hepatitis B Virus (HBV)
·
1481. Diagnostic
Accuracy of Blood Tests of Liver Fibrosis in Chronic Hepatitis B: Comparison
with Hepatitis C
Treatment
Barriers
·
1474. Barriers to Viral
Hepatitis Treatment for At-Risk Groups: Impacts of Policies and Processes
Guidelines
·
936. Predictors Of Significant
Histological Findings In Chronic Hepatitis B Patients With Persistently Normal
ALT Levels
·
937. Treatment-induced HBeAg
Seroconversion Is a Poor Therapeutic Endpoint
·
942. A High Prevalence of
Significant Liver Disease in Asymptomatic Hepatitis B Patients with High Viral
Load; Candidates for Antiviral Therapy
·
944. Oncologists and Hepatitis
B: Results of a Questionnaire Survey to Determine Their Current Level of
Awareness and Clinical Practice of Antiviral Prophylaxis to Prevent Reactivation
·
945. Pre-emptive Lamivudine
Reduces the Risk of Chemotherapy-Induced HBV-Related Morbidity and Mortality in
HBsAg-Positive Cancer Patients: Meta-analysis
·
968.Estimating the Impact of
Chronic Hepatitis B on Future Liver-related Morbility, Mortality and Cost in
Spain
·
971. Predictors of Liver
Decompensation in HBeAg–negative Patients with Chronic Hepatitis B
Virology
·
87. Dual Over-expression of Insulin Receptor Substrate-1
and Hepatitis Bx Gene Causes Pre-malignant Changes in Liver
·
111. Powerful Inhibition of Hepatitis B
Virus Replication by CpG-induced Cytokines in Combination with Lamivudine In
Vitro
·
109. In Vitro and In Vivo Inhibition of HBV
Replication by Peptide Aptamers Via Disruption of the HBX-Proteasome
Interaction
·
110. Induction of Antigen-Specific Humoral
and Cellular Immune Responses by Antigen-Pulsed Human Blood Dendritic Cells in
Hepatitis B Vaccine Nonresponders and Patients with Chronic Hepatitis B
·
112. Long Term Inhibition of Hepatitis B
Virus Replication Using the Non Viral Episomal Vector pEPI-1
·
113. Adeno-associated Virus Rep78 Protein
Inhibits Human Hepatitis B Virus Replication in Human Cells by Binding to X
Promoter and C Promoter of HBV
·
114. Construction of the shRNA Plasmid of
Human fgl2 Prothrombinase Gene and Its Effect on hfgl2 Expression In Vitro
·
146. Chronic HBV Evolution Is Associated with
Numeric and Phenotypic Changes in Peripheral HBV-core Epitope-Specific CD4+
T-cells: A Study Using a Novel HBV-core-Specific HLA-DRB1*0101 Tetramer for the
Analysis of Antiviral CD4+ T-cell Responses During Acute and Chronic Hepatitis
B
·
146. Chronic HBV Evolution Is Associated
with Numeric and Phenotypic Changes in Peripheral HBV-core Epitope-specific
CD4+ T-cells: A Study Using a Novel HBV-core Specific HLA-DRB1*0101 Tetramer
for the Analysis of Antiviral CD4+ T-cell Responses During Acute and Chronic
Hepatitis B
·
1031. Higher Percentages of Intra-Hepatic
Regulatory T Cells Are Present in Chronic Hepatitis B Patients with a High
Viral Load
·
1032. Antigen-pulsed Dendritic Cells Are
Capable of Inducing Both Innate ad Adaptive Immunity: A Lesson Learned from
Cross-Talk Between Natural Killer Cells and Dendritic Cells and Their
Application for Immune Therapy of Chronic Hepatitis B Virus Infection
·
1042. Expression of Notch Signaling and
Antigen Processing Molecules in Progressive Pathogenenic Biopsies of Chronic
Hepatitis B Infection
·
1043. Intrahepatic Status of Regulatory T
cells in Autoimmune Hepatitis, Primary Biliary Cirrhosis, Chronic Hepatitis C,
and Chronic Hepatitis B
·
1460. Differential Role of Liver-targeted Regulatory
T Cell to Hepatitis B and C Virus in Chronically Infected Patients
·
1467. Quantitative Detection of Integrated
HBV Surface Gene Sequences in the Liver by Real-Time PCR